Novo Nordisk's Buyback and Breakthrough Paint a Complex Picture

Novo Nordisk executes major share buybacks and announces positive Phase 3 results for sickle cell drug etavopivat, pressuring rival Agios. Stock remains below highs.

Novo Nordisk's stock remains under pressure, trading around €34.40 and still roughly 23% below its 52-week high. Yet recent corporate actions reveal a company actively navigating this turbulence, deploying capital for shareholder returns while notching a significant clinical victory that has sent shockwaves through a competitor.

On April 20, the Danish pharmaceutical giant delivered a dual update to the market. The first concerned its ongoing share repurchase program. Since its initiation on February 4, 2026, Novo Nordisk has bought back approximately 12.3 million of its own B-shares at an average price of 256.87 Danish kroner (DKK). This represents a total transaction value of nearly 3.15 billion DKK. The company is currently executing a sub-program targeting up to 3.8 billion DKK in buybacks by early May, of which about 83% has already been utilized. The broader authorization allows for repurchases of up to 15 billion DKK over a twelve-month period. These moves have increased the company's treasury stock to nearly 30 million B-shares, equivalent to 0.7% of its total share capital.

Simultaneously, Novo Nordisk announced positive top-line results from its HIBISCUS Phase 3 trial for etavopivat. The oral, once-daily drug, intended to treat sickle cell disease, met both co-primary endpoints in a study involving 385 patients aged twelve and older. Compared to a placebo, etavopivat reduced the annualized rate of vaso-occlusive crises by 27% and significantly extended the time to first crisis from 20.9 to 38.4 weeks. A standout secondary endpoint showed 48.7% of patients achieved a hemoglobin increase of more than 1 g/dL after 24 weeks, versus just 7.2% in the placebo group.

The clinical success had immediate repercussions for U.S. rival Agios Pharmaceuticals, whose stock plummeted 23% on the news. Agios's competing drug, mitapivat, also improves hemoglobin levels but previously failed to meet its primary endpoint of reducing crises. Analysts at Truist Securities noted the data creates "separation among the PK class candidates," though no head-to-head studies between the two treatments exist yet. Novo Nordisk, which gained access to etavopivat through its 2022 acquisition of Forma Therapeutics, plans to submit regulatory filings in the second half of 2026. The drug holds Fast Track, Orphan Drug, and Rare Pediatric Disease designations in the U.S., and Orphan Drug status in the EU.

This breakthrough in a market serving an estimated eight million people worldwide represents a strategic step for Novo Nordisk in diversifying beyond its core GLP-1 franchise. However, investor sentiment remains cautious. Major banks including JPMorgan, Jefferies, and Goldman Sachs maintain neutral ratings on the stock. JPMorgan recently cut its price target to 250 DKK, citing disappointing clinical data for another pipeline drug, CagriSema. The stock's technical picture is mixed: while it has gained about 12% from a late-March low and trades just above its 50-day moving average, a Relative Strength Index (RSI) reading below 25 indicates shares are technically oversold. The equity continues to trade well below its 200-day line.

All eyes now turn to May 6, 2026, when Novo Nordisk reports its first-quarter results. This will be the company's first comprehensive update since the CagriSema setback. Management's existing full-year guidance, forecasting a currency-adjusted decline in both sales and operating profit of 5% to 13%, will be in focus. The upcoming report and further commentary on the pipeline following the etavopivat data are seen as the next major catalysts for the stock's direction.